Versiti - Qizhen Shi Grant Support | Versiti Blood Research Institute

Grant Support


Qizhen Shi, MD, PhD, and her laboratory have been awarded a number of grants that help them propel their lifesaving hemophilia A and hemophilia B research.

Recent grants include:

  • R01 HL102035, “Platelet-derived FVIII gene therapy of hemophilia A,” Role: PI (2010-2024)
  • R01 HL142791, “A phase I clinical trial testing feasibility of hematopoietic stem cell gene therapy using platelet FVIII to safely improve hemostasis for severe hemophilia A with inhibitory antibodies to FVIII,” Role: Co-I (2019-2024)
  • Joan Cox Gill CCBD/MSI Clinical & Translational Pilot Award, "Evaluating T follicular helper cells in FVIII inhibitor development and ITI in patients with Hemophilia A", Role: PI (2021-2023)”.

MACC FUND, “FVIII immune responses in hemophilia A,” Role: PI

In her laboratory, Qizhen Shi is supported by lab staff including a research technologist, postdoctoral fellow and animal technicians.
Qizhen Shi, MD, PhD, has been published in numerous scientific and medical journals for her research of hemophilia A and hemophilia B.
Qizhen Shi Laboratory
The Qizhen Shi, MD, PhD, laboratory at Versiti Blood Research Institute studies gene and cell therapies for treatment of hemophilia A and hemophilia B.
Qizhen Shi, MD, PhD
Dr. Shi is a senior investigator at Versiti Blood Research Institute who studies new treatments for patients with hemophilia.